Cadrenal Therapeutics (CVKD) Institutional Ownership $16.17 +1.68 (+11.59%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Cadrenal Therapeutics (NASDAQ:CVKD)CurrentInstitutional OwnershipPercentage7.92%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)2 Get CVKD Insider Trade Alerts Want to know when executives and insiders are buying or selling Cadrenal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Cadrenal Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/9/2024 Renaissance Technologies LLC59,491$28K0.0%-59.8%0.372% 2/13/2024 Armistice Capital LLC414,285$307K0.0%-57.8%3.182% 11/15/2023 Armistice Capital LLC982,285$668K0.0%N/A7.544% (Data available from 1/1/2016 forward) CVKD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CVKD shares? During the previous two years, the following institutional investors and hedge funds held shares of Cadrenal Therapeutics shares: Armistice Capital LLC ($307K), Renaissance Technologies LLC ($28K).Learn more on CVKD's institutional investors. What percentage of Cadrenal Therapeutics stock is owned by institutional investors? 7.92% of Cadrenal Therapeutics stock is owned by institutional investors. Learn more on CVKD's institutional investor holdings. Which institutional investors have been buying Cadrenal Therapeutics stock? The following institutional investors have purchased Cadrenal Therapeutics stock in the last 24 months: Armistice Capital LLC ($982.29K). How much institutional buying is happening at Cadrenal Therapeutics? Institutional investors have bought a total of 982,285 shares in the last 24 months. This purchase volume represents approximately $0.00 in transactions. Which Cadrenal Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Cadrenal Therapeutics stock in the last 24 months: Armistice Capital LLC ($568K), and Renaissance Technologies LLC ($88.65K). How much institutional selling is happening at Cadrenal Therapeutics? Institutional investors have sold a total of 656,647 shares in the last 24 months. This volume of shares sold represents approximately $0.00 in transactions. Related Companies UNCY Institutional Ownership PDSB Institutional Ownership EPIX Institutional Ownership VOR Institutional Ownership ANVS Institutional Ownership VTGN Institutional Ownership OPTN Institutional Ownership RPTX Institutional Ownership VHAQ Institutional Ownership BCAB Institutional Ownership This page (NASDAQ:CVKD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
